Biotech Allakos Inc. /zigman2/quotes/203639566/composite ALLK -2.11% priced its initial public offering at $18 a share, above its $15 to $17 price range. The clinical-stage company, which focuses on developing antibodies for the treatment of eosinophil and mast cell related diseases, sold 7.1 million shares to raise $127.8 million. Shares will start trading later Thursday on Nasdaq, under the ticker symbol "ALLK."
/zigman2/quotes/203639566/composite
Add to watchlist
ALLK
Add to watchlist
ALLK
US
: U.S.: Nasdaq
$
4.63
-0.10
-2.11%
Volume: 375,099
March 24, 2023 2:46p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$405.28 million
Rev. per Employee
N/A
